ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1541	National Cancer Institute	Html	en	Testicular Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of testicular cancer.	tumor marker levels 0.613741 cancer treatment 0.320393 testicle 0.4399 testicular cancer spreads 0.297436 contains cancer cells 0.273957 body 0.340237 PDQ cancer information 0.333395 testicular cancer 0.725943 testicular germ cell 0.272075 clinical trial search 0.331245 long-term follow-up 0.27959 clinical trials 0.622305 undescended testicle 0.275057 cancer information summary 0.310365 clinical trial 0.428741 spermatic cord 0.329024 tumor markers 0.368096 inguinal orchiectomy 0.361937 patients 0.336056 malignant tumor cells 0.300585 NCI PDQ cancer 0.275949 lymph nodes 0.529321 radiation therapy 0.376906 Serum tumor marker 0.305709 general cancer information 0.270473	treatment 0.469864 general information 0.294195 NCI-supported cancer 0.288405 cancer cells 0.405185 Recurrent testicular cancer 0.320003 Cancer Information Service 0.271409 treatment clinical trials 0.292646 National Cancer Institute 0.350045 lymph vessels 0.288149 new treatment 0.293694 distant lymph nodes 0.317031 combination chemotherapy 0.304741 Testicular Cancer Treatment 0.305239 metastatic tumor 0.2721 blood 0.282323 tumor marker test 0.304459 retroperitoneal lymph nodes 0.28218 cancer clinical trials 0.344359 stage 0.329917 testicular tumor 0.289398 comprehensive cancer information 0.269733 cancer 0.908321 information 0.339805 following tumor markers 0.277178	CLICK HERE
1741	National Cancer Institute	Html	en	Menopausal Hormone Therapy and Cancer	A fact sheet about the results of research on menopausal hormone therapy (MHT). Includes information about the effect of MHT on the body and benefits and risks of using menopausal hormones.	M. Menopausal hormone 0.399446 estrogen 0.661955 progestin 0.473666 menopausal symptoms 0.433158 lung cancer 0.436349 postmenopausal estrogen 0.401234 Anderson GL 0.391175 Breast Cancer Research 0.404812 MHT 0.573747 placebo 0.469804 whi estrogen-plus-progestin study 0.43139 colorectal cancer 0.510049 breast cancer survivors 0.442442 vertebral fractures 0.396082 hormone therapy group 0.403745 hormone therapy medication 0.406528 hot flashes 0.474358 invasive breast cancer 0.436727 hormone replacement therapy 0.391432 Health Initiative 0.489409 randomized clinical trials 0.471592 menopausal hormone therapy 0.725067 WHI trials 0.489874 health effects 0.386028 women 0.908896	MHT change 0.392923 breast cancer detection 0.43656 Non-FDA-approved hormone products 0.402601 One-third lower risk 0.39906 breast cancer recurrence 0.408176 breast cancers 0.398762 estrogen-alone MHT 0.393357 10,000 women 0.558208 National Cancer Institute 0.442573 natural hormones estrogen 0.458568 hormone therapy 0.86696 combined hormone therapy 0.473354 postmenopausal women 0.502051 absolute terms 0.40498 breast cancer 0.990788 WHI Estrogen-Alone Study 0.441842 Chlebowski RT 0.451885 randomized controlled trial 0.389145 healthy postmenopausal women 0.397371 et al 0.576891 New England Journal 0.390547 breast cancer incidence 0.436953 Women’s Health 0.429633 risk 0.448458	CLICK HERE
2076	National Cancer Institute	Html	es	Alcohol y el riesgo de cáncer	Hoja informativa que resume la comprobación de la relación entre el consumo de alcohol y el riesgo de varios cánceres. Incluye información de los factores que afectan el riesgo de cánceres asociados con el alcohol, como son los genes y el uso de tabaco.	Neck Cancer Epidemiology 0.538614 Lancet Oncology 0.534891 Hirose K 0.511352 Matsuo K 0.510531 levadura fermenta azúcares 0.523222 pharyngeal cancers 0.510877 Alcohol drinking cessation 0.626157 British Journal 0.511017 vitamina a 0.51094 Straif K 0.510855 vitamina e 0.511443 IARC Monographs 0.512402 IARC Working Group 0.518509 riesgos resultantes 0.517271 Estados Unidos 0.591854 alcohol drinking 0.759868 Tajima K 0.511125 PubMed Abstract 0.957874 neck cancers 0.610459 Cancer Epidemiology 0.551257 Beral V 0.510723 Liver Disease 0.511887 cancer prevention 0.54975 alcohol consumption with 0.621668 vino tinto 0.531211	results from subgroup 0.518268 International Head 0.510721 Fedirko V 0.510662 contaminantes cancerígenos 0.510849 Carcinogenic Risks 0.530612 ADH hiperactiva 0.535244 Numerosos estudios 0.516257 preclinical studies 0.511192 enzima hiperactiva 0.522144 Bonifazi M 0.510536 epidemiological studies 0.512501 Hodgkin lymphoma 0.511109 enzima adh hiperactiva 0.532963 Tramacere I 0.552596 genetic polymorphisms 0.530043 enzima llamada 0.519065 Bagnardi V 0.51066 Rehm J 0.529488 cabo estudios 0.515059 pooled analysis 0.527827 renal cell carcinoma 0.521274 Cancer Institute 0.525901 células renales 0.53114 New York Academy 0.514614	CLICK HERE
2110	National Cancer Institute	Html	es	Exámenes de detección del cáncer de esófago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar el cáncer de esófago.	upper gastrointestinal tract 0.43004 Cancer Research Fund 0.484546 brush cytology as 0.429018 Lagergren J 0.555033 Gastrointest Endosc 0.477141 American Cancer Society 0.678403 stains intestinal metaplasia 0.429485 oesophagus along caspian 0.427264 gastroesophageal reflux 0.489709 fármacos relajantes 0.451925 Spechler SJ 0.485427 Symptomatic gastroesophageal reflux 0.437613 Instituto Nacional 0.453917 brush off this 0.427799 Dawsey SM 0.483008 Bergström R 0.555203 PDQ Exámenes 0.458666 Estados Unidos 0.464483 Natl Cancer Inst 0.581715 múltiples estudios 0.436926 intestinal metaplasia 0.447925 Blot WJ 0.441725 Aliment Pharmacol Ther 0.427038 esophageal cancer 0.945046 gastrointestinal tract 0.444979	Endoscopic Screening Study 0.437695 Barrett quizás 0.452361 does lugol staining 0.427191 Cancer Facts 0.485513 Petras RE 0.445899 hallazgos histológicos simultáneos 0.432023 villas norteñas vs 0.429133 Norman Barrett 0.453271 riesgo quizás 0.428246 pan-esophageal brush cytology 0.43018 Cancer Research 0.525303 National Cancer Institute 0.476234 gastric carcinoma 0.452643 Epidemiol Biomarkers Prev 0.482868 Thorac Cardiovasc Surg 0.430717 alcoholics using endoscopy 0.428611 Intern Med 0.449117 outpatient gi endoscopy 0.428057 seroepidemiologic case-control study 0.429272 risk factor 0.46512 prospective follow-up study 0.432873 squamous cell dysplasia 0.434246 brush cytology 0.443313 Preoperative risk analysis 0.436183	CLICK HERE
3435	National Cancer Institute	Html	es	Riesgo de cáncer de seno en mujeres estadounidenses	Hoja informativa que presenta estadísticas sobre el riesgo que tiene una mujer de padecer cáncer de seno (mama) e información sobre los factores de riesgo del cáncer de seno.	Risk Assessment Tool 0.544579 familiar masculino 0.474027 siguientes estimaciones 0.491803 siguientes factores 0.486246 carcinoma lobulillar 0.472032 Estados Unidos 0.992188 Determinados cambios 0.507031 abortos espontáneos 0.47065	características anormales 0.475549 largo plazo 0.483682 Antecedentes familiares 0.466654 determinados genes 0.674691 mujer estadounidense promedio 0.835519 SEER Cancer Statistics 0.593996 fármaco des 0.469829	CLICK HERE
3527	National Cancer Institute	Html	es	Cáncer de próstata, nutrición y suplementos alimentarios (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de la nutrición y los suplementos alimentarios para disminuir el riesgo de presentar cáncer de próstata o como tratamiento del mismo.	World Cancer Research 0.326698 Cancer Research Fund 0.313691 Causes Control 0.305123 Sin embargo 0.321932 accessed october 0.306323 productos lácteos 0.431605 vitamina d 0.31442 ayunas polyphenon 0.305303 Preventive Services Task 0.311029 vitamina e 0.30874 Instituto Nacional 0.305332 GEGC Estado Duración 0.307099 ratones tramp 0.382139 among men with 0.325726 Estados Unidos 0.340412 Natl Cancer Inst 0.313037 Ayunas Dosis 0.305586 PDQ Prevención 0.307 men with 0.346832 systematic evidence review 0.313097 prostate tumor 0.309841 cohort studies 0.305885 Cancer Prostate Sweden 0.316805 cohort study 0.307709 Boon H 0.305432	vitamin d 0.306351 dietary calcium 0.324651 diagnosed with 0.308047 Prostate CAncer Therapy 0.319442 Nutr Cancer 0.324876 as risk factors 0.306238 alto consumo 0.312193 Cancer Research 0.341162 Cancer Care 0.312902 Epidemiol Biomarkers Prev 0.355426 Mitrou PN 0.306395 Clin Nutr 0.308257 subsequent risk 0.305051 estudio pcats 0.30523 Services Task Force 0.310689 principales fuentes 0.3052 systematic review 0.306566 risk factor 0.3097 Dietary calcium does 0.306286 prostate cancer 0.981425 Albanes D 0.30581 Polyphenon E 0.333052 risk with specific 0.307113 dairy products 0.430021	CLICK HERE
3651	National Cancer Institute	Html	en	TAILORx Trial Shows Women at Low Risk for Breast Cancer Recurrence May Forgo Chemotherapy	A summary of results from the Trial Assigning Individualized Options for Treatment, or TAILORx, finds that women with early-stage hormone receptor-positive breast cancer have a low risk of recurrence based on a test for the expression of 21 genes.	adjuvant chemotherapy 0.787463 higher recurrence scores 0.454387 21-gene recurrence score 0.676351 mid-range score 0.364833 postsurgical chemotherapy 0.404675 Jo Anne Zujewski 0.399515 Cancer Therapy Evaluation 0.426635 National Clinical Trials 0.404942 adult cancer research 0.415943 early-stage breast cancer 0.44803 Montefiore Medical Center 0.406438 test’s ability 0.364803 lowest 21-gene recurrence 0.476043 patients 0.383684 5-year recurrence rates 0.497417 Trial Assigning Individualized 0.434763 hormone receptor-positive breast 0.606376 gene panel test 0.401972 high risk 0.363068 primary breast cancers 0.421261 women 0.592588 low risk 0.421557 United States 0.429126 ECOG-ACRIN Research Group 0.402947	low-risk subset 0.454616 breast cancer recurrence 0.516723 percent 0.443551 Initial findings 0.364086 hormone receptor-positive disease 0.474523 10,000 women 0.389687 molecular test 0.368711 21-gene panel test 0.405027 various treatment options 0.412166 hormone therapy 0.89376 aromatase inhibitor therapy 0.427967 primary cancer events 0.412638 NCIC-Clinical Trials Group 0.404753 postoperative treatment 0.371444 estrogen receptor 0.368053 early-stage hormone 0.432936 breast cancer 0.917923 21-gene recurrence test 0.48221 Recurrence events 0.412295 breast cancer mortality 0.453698 -positive breast cancer 0.464645 New England Journal 0.424409 HER2-negative breast cancer 0.446932 journal article 0.367547	CLICK HERE
16693	National Cancer Institute	Html	en	In an Era of Precision Medicine, Testing New Approaches to Breast Cancer Screening	An NCI research article about individualized approaches that could help identify those at risk of breast cancer who need to be screened and testing screening intervals that are appropriate for each person’s level of risk.	clinical DNA testing 0.255296 certain genetic alterations 0.26295 Family Comprehensive Cancer 0.304528 early molecular changes 0.250583 Breast Cancer Surveillance 0.393407 Dr. Szabo 0.324259 Breast Care Center 0.362601 ovarian cancer patients 0.316413 clinical trial 0.331236 breast cancer prevention 0.392842 breast density 0.431317 annual mammography 0.280302 risk-based group 0.308284 breast MRI 0.280239 Dr. Tice 0.272786 molecular changes 0.271002 seminal clinical trials 0.251623 Consortium Risk Calculator 0.280953 risk-based approach 0.302169 high risk 0.287254 precision medicine 0.358439 genetic markers 0.26055 women 0.30866 risk-based screening arm 0.644595 annual mammograms 0.27926	hereditary breast 0.275314 cancer screening 0.642713 cancer prevention 0.415329 HBOC—for genetic alterations 0.253144 risk-based screening strategies 0.470957 advanced-stage breast cancers 0.351274 family medical history 0.264412 General Internal Medicine 0.258705 Cancer MoonshotSM Blue 0.314025 risk-based screening 0.987559 false-positive test results 0.2742 lowest risk scores 0.302649 strongest risk factor 0.279896 breast cancer risk 0.568335 screening interval 0.333337 breast cancer 0.836019 genetic alterations 0.266377 annual screening group 0.404487 risk factor 0.298033 precision cancer prevention 0.325999 risk prediction model 0.28587 WISDOM trial 0.343878 highest risk scores 0.301801 ovarian cancer syndrome 0.315021	CLICK HERE
17277	National Cancer Institute	Html	null	Cáncer avanzado y quienes cuidan	Si usted cuida a un paciente, puede sentir cansancio y preocupación a medida que se enfrenta al cáncer de su ser querido. Cuidar a alguien con cáncer avanzado trae desafíos y preocupaciones nuevas.			CLICK HERE
17288	National Cancer Institute	Html	es	Personal de atención para la salud	Información sobre el equipo de tratamiento de proveedores de salud que trabajan juntos para ayudar a pacientes con cáncer.	cuáles alimentos 0.989407		CLICK HERE